Danazol treatment of idiopathic myelofibrosis with severe anemia

Haematologica

Volumn 85, Issue 6, 2000, Pages 595-599

  Cervantes, Francisco ^a   Hernández Boluda, Juan Carlos ^b   Alvarez, Alberto ^b   Nadal, Elisabet ^b   Montserrat, Emilio ^b  

^a HOSPITAL CLÍNIC   (Spain)

^b NONE

Author keywords

Androgens; Anemia; Danazol; Idiopathic myelofibrosis; Treatment

Indexed keywords

CYCLOSPORIN A; DANAZOL; HEMOGLOBIN; HYDROXYUREA; OXYMETHOLONE; PREDNISONE;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ANDROGEN THERAPY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; DRUG TOLERABILITY; ERYTHROCYTE TRANSFUSION; FEMALE; HEADACHE; HUMAN; HUMAN CELL; MALE; MYELOFIBROSIS; REFRACTORY ANEMIA; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTE COUNT; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; DANAZOL; DRUG EVALUATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MYELOFIBROSIS; PLATELET COUNT; SPLENOMEGALY; TREATMENT OUTCOME;

EID: 18844467494     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Jacobson RJ, Salo A, Fialkow PJ. Agnogenic myeloid metaplasia: a clonal proliferation of hematopoietic stem cells with secondary myelofibrosis. Blood 1978; 51:189-94.
2. Reilly JT. Pathogenesis and management of idiopathic myelofibrosis. Baillière Clin Haematol 1998; 751-77.
3. Centenara E, Guarnone R, Ippoliti G, Barosi G. Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report. Haematologica 1998; 83:622-6.
4. Kennedy BJ. Effect of androgenic hormone in myelofibrosis. JAMA 1962; 182:114-9.
5. Silver RT, Jenkins DE Jr, Engle RL. Use of testosterone and busulfan in the treatment of myelofibrosis with myeloid metaplasia. Blood 1964; 23:341-53.
6. Besa EC, Nowell PC, Geller NL, Gardner FH. Analysis of the androgen response of 23 patients with agnogenic myeloid metaplasia: the value of chromosomal studies in predicting response and survival. Cancer 1982; 49:308-13.
7. Hast R, Engstedt L, Jameson S, et al. Oxymetholone treatment in myelofibrosis. Blut 1978; 37:19-26.
8. Chabannon C, Pegourie B, Sotto JJ, Hollard D. Clinical and hematological improvement in a patient receiving danazol therapy for myelofibrosis with myeloid metaplasia. Nouv Rev Fr Hematol 1990; 32: 165-6.
9. Levy V, Bourgarit A, Delmer A, et al. Treatment of agnogenic myeloid metaplasia with danazol: a report of four cases. Am J Hematol 1996; 53:239-41.
10. Cervantes F, Pereira A, Esteve J, et al. Identification of "short-lived" and "lone-lived" patients at presentation of idiopathic myelofibrosis. Br J Haematol 1997; 97:635-40.
11. Lennert K, Naghai K, Schwarze EW. Patho-anatomical features of the bone marrow. Clin Haematol 1975; 4:331-51.
12. Hasselbach H. Idiopathic myelofibrosis: a clinical study of 80 patients. Am J Hematol 1990; 4:291-300.
13. Cervantes F, Pereira A, Esteve J, Cobo F, Rozman C, Montserrat E. The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. Eur J Haematol 1998; 58:101-5.
14. Njoku OS, Lewis SM, Catovsky D, Gordon-Smith EC. Anaemia in myelofibrosis: its value in prognosis. Br J Haematol 1983; 54:79-89.
15. Barosi G, Berzuini C, Liberato LN, Costa A, Polino G, Ascari E. A prognostic classification of myelofibrosis with myeloid metaplasia. Br J Haematol 1988; 70:397-401.
16. Visani G, Finelli C, Castelli U, et al. Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. Br J Haematol 1990; 75:4-9.
17. Dupriez B, Morel P, Demory JL, et al. Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013-8.
18. Cervantes F, Barosi C, Demory JL, et al. Myelofibrosis with myeloid metaplasia in young individuals: disease characteristics, prognostic factors and identification of risk groups. Br J Haematol 1998; 102:684-90.
19. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société FranÇaise de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999; 93:2831-8.
20. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 1983; 308:1396-9.
21. Ahn YS, Harrington WJ, Mylvaganam M, Ayub J, Pall LM. Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med 1985; 102:298-301.
22. Stadtmauer EA, Cassileth PA, Edelstein M, et al. Danazol treatment of myelodysplastic syndromes. Br J Haematol 1991; 77:502-8.
23. Barosi G, Ambrosetti A, Finelli C, et al. The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. Br J Haematol 1999; 104:730-7.
24. Centenara E, Guarnone R, Ippoliti G, Barosi G. Cyclosporin-A in severe refractory anemia of myelofibrosis with myeloid metaplasia: a preliminary report. Haematologica 1998; 83:622-6.
25. Thomas DA, Aguayo A, Giles FJ, et al. Thalidomide anti-angiogenesis therapy in Philadelphia-negative myeloproliferative disorders and myelofibrosis. Blood 1999; 10(Suppl 1):702a.